Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS To Examine Clinical Benefit, Cost When Creating New OPPS Categories

This article was originally published in The Gray Sheet

Executive Summary

The Centers for Medicare & Medicaid Services is asking manufacturers to provide examples of medical technologies for which transitional "pass-through" payments might be appropriate even if the device itself does not provide an obvious improvement in beneficiary outcomes over existing technologies

You may also be interested in...



OPPS Final Rule Carries Higher Offsets For Cardiovascular Device Procedures

Procedures using cardiovascular devices will be reimbursed at a relatively high rate in calendar 2002 under the Centers for Medicare & Medicaid Services' final rule on the hospital outpatient prospective payment system (OPPS)

OPPS Final Rule Carries Higher Offsets For Cardiovascular Device Procedures

Procedures using cardiovascular devices will be reimbursed at a relatively high rate in calendar 2002 under the Centers for Medicare & Medicaid Services' final rule on the hospital outpatient prospective payment system (OPPS)

MedPAC To Address Future Of “Pass-Through” Payments In March Report

The Medicare Payment Advisory Commission will consider long-term strategies for the reimbursement of medical technology in the hospital outpatient setting and make a recommendation in its March 2002 report to Congress

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel